AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings

AstraZeneca CEO Pascal Soriot said Monday that the company’s use of artificial intelligence in drug design and development has not yet produced any clinical-stage drug candidates. Soriot added, however, that AI could still prove useful in improving the odds of success for drugs already in later stages of development.

The remarks, reported by Endpoints News, frame AI’s near-term value at AstraZeneca less as a discovery engine and more as a tool for managing risk in trials that are already underway. Soriot’s comments suggest a company recalibrating expectations for AI in drug development, moving from hopes of AI-originated molecules toward a narrower, more immediate application, easing the uncertainty that attends late-stage clinical work and, potentially, speeding regulatory filings.

The distinction Soriot drew, between AI’s unproven role in generating new drug candidates and its possible role in de-risking existing ones, indicates where the company currently sees measurable value. No clinical-stage candidate has yet emerged from AstraZeneca’s AI-driven design efforts, by Soriot’s own account.

The report positions AstraZeneca among major pharmaceutical firms testing artificial intelligence against the practical demands of drug development, rather than treating it as a speculative or purely experimental pursuit. Soriot’s framing ties AI’s promise to concrete late-stage outcomes, success rates and filing timelines, rather than to earlier-stage discovery work, where results at AstraZeneca have not yet materialized.